Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer

References

• Gettinger S, Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med. 2011;32:839–851.
   PubMed Web of Science ®Google Scholar
• Jansen R, Slingerland R, Goey S, et al. Interleukin-2 andinterferon-alpha in the treatment of patients withadvanced non-small-cell lung cancer. J Immunother. 1992;12:70–73.
   PubMed Web of Science ®Google Scholar
• Schiller J, Morgan-Ihrig C, Levitt M. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol. 1995;18:47–51.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Fehrenbacher L, Spira AI, et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). European Cancer Congress 2015; Sep 25–29. Abstract 14LBA.
   Google Scholar
• Sundar R, Cho B-C, Brahmer JR, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85–96.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Keir M, Butte M, Freeman G, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389–395.
   PubMed Web of Science ®Google Scholar
• Mu C, Huang J, Chen Y, et al. High expression of PD-L1 in lung cancermay contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682–688.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti- CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18:206–213.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 [Internet]. [cited 2015 Nov 13]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
   Google Scholar
• Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Brahmer JR, Ou SI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). 2015 ASCO Annual Meeting. Abstract 8032.
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046–2054.
   PubMed Web of Science ®Google Scholar
• Rizvi N, Gettinger SN, Goldman J, et al. Safety and efficacy of first-line nivolumab (Anti-programmed death-1 [PD‐1]) and ipilimumab in non-small cell lung cancer (NSCLC). 16th World conference on lung cancer. 2015 Sep 7. Abstract ORAL02.05.
   Google Scholar
• Antonia SJ, Bendell J, Taylor M, et al. Phase I/II study (CheckMate 032) of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC). 2015 ASCO Annual Meeting. 2015. Abstract 7503.
   Google Scholar
• Patnaik AM, Socinski MA, Gubens MA, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. 2015 American society of clinical oncology annual meeting. 2015. Abstract 8011.
   Google Scholar
• Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol (Copenh). 1993;129:31–38.
   PubMedGoogle Scholar
• Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303–307.
   PubMed Web of Science ®Google Scholar
• Melmed S, Polonsky KS, Larsen, PR. Williams textbook of endocrinology. 12th ed. Philadelphia (PA): Elsevier; 2011. ISBN: 978-1-4377-0324-5.
   Google Scholar
• Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24:1670–1751.
   PubMed Web of Science ®Google Scholar
• Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371–381.
   PubMed Web of Science ®Google Scholar
• Borodic G, Hinkle DM, Cia Y. Drug-induced Graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg. 2011;27:e87-8.
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, Paragliola RM, et al. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013;169:R153-64.
   PubMed Web of Science ®Google Scholar
• Mahzari M, Liu D, Arnaout A, et al. Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diab. 2015;8:21–28.
   PubMed Web of Science ®Google Scholar
• Barnard ZR, Walcott BP, Kahle KT, et al. Hyponatremia associated with ipilimumab-induced hypophysitis. Med Oncol. 2012;29:374–377.
   PubMed Web of Science ®Google Scholar
• Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13:29–38.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
   PubMed Web of Science ®Google Scholar
• Chow LQM. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small-cell lung cancer. Am Soc Clin Oncol Educ Book. 2013. doi:10.1200/EdBook_AM.2013.33.e280. [Epub ahead of print]
   Google Scholar
• Antonia SJ, Goldberg SB, Balmanoukian AS, et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol (Meeting Abstracts). 2015 May;33(15):suppl 3014.
   Web of Science ®Google Scholar
• Oxnard GR, Ramalingam SS, Ahn M, et al. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. J Clin Oncol (Meeting Abstracts). 2015 May;33(15):suppl 2509.
   Web of Science ®Google Scholar
• Creelan BC, Chow LQ, Kim D, et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PDL1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2015 May;33(15):suppl 3047.
   Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681–6688.
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053.
   PubMed Web of Science ®Google Scholar
• Bouwhuis MG, Ten Hagen TLM, Suciu S, et al. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol. 2011;23:170–176.
   PubMed Web of Science ®Google Scholar